Akamis Bio Revenue and Competitors
Employee Data
- Akamis Bio has 42 Employees.
- Akamis Bio grew their employee count by -30% last year.
Akamis Bio's People
| Name | Title | Email/Phone |
|---|
Akamis Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 86 | 4% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 680 | 30% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5095 | 12% | N/A | N/A |
What Is Akamis Bio?
Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI) To learn more, please visit www.akamisbio.com.
keywords:N/A
N/A
Total Funding
42
Number of Employees
N/A
Revenue (est)
-30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Abingdon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 42 | 11% | N/A |
#2 | $5M | 42 | -2% | N/A |
#3 | $6.7M | 43 | -7% | N/A |
#4 | $19M | 45 | -10% | N/A |
#5 | $10.2M | 49 | -9% | N/A |